V CJD (VARIANT CREUTZFELDT JAKOB DISEASE)
\vˈiː sˌiːd͡ʒˌe͡ɪdˈiː vˈe͡əɹi͡ənt krjˈuːtsfɛlt d͡ʒˈakɒb dɪzˈiːz], \vˈiː sˌiːdʒˌeɪdˈiː vˈeəɹiənt krjˈuːtsfɛlt dʒˈakɒb dɪzˈiːz], \v_ˈiː s_ˌiː_dʒ_ˌeɪ_d_ˈiː__ v_ˈeə_ɹ_iə_n_t k_r_j_ˈuː_t_s_f_ɛ_l_t dʒ_ˈa_k_ɒ_b d_ɪ_z_ˈiː_z]\
Sort: Oldest first
-
A rare transmissible encephalopathy most prevalent between the ages of 50 and 70 years. Affected individuals may present with sleep disturbances, personality changes, ATAXIA; APHASIA, visual loss, weakness, muscle atrophy, MYOCLONUS, progressive dementia, and death within one year of disease onset. A familial form exhibiting autosomal dominant inheritance and a new variant CJD (potentially associated with ENCEPHALOPATHY, BOVINE SPONGIFORM) have been described. Pathological features include prominent cerebellar and cerebral cortical spongiform degeneration and the presence of PRIONS. (From N Engl J Med, 1998 Dec 31;339 (27))
By DataStellar Co., Ltd
Word of the day
Proto Oncogene Proteins c erbB 2
- cell surface protein-tyrosine kinase that is found to be overexpressed in significant number adenocarcinomas. It has extensive homology can heterodimerize EGF EPIDERMAL GROWTH FACTOR), 3 receptor (RECEPTOR, 3) and the 4 receptor. Activation of erbB-2 receptor occurs during heterodimer formation with a ligand-bound erbB family members. EC 2.7.11.-.
Nearby Words
- v abl gene
- v abl genes
- v abl oncogene
- v abl oncogenes
- v abl proteins
- V CJD (Variant Creutzfeldt Jakob Disease)
- v erba gene
- v erba genes
- v erba oncogene
- v erba oncogenes
- v erba proteins